Key Highlights
- H1 Revenue to 31 March 2026 rose 6.1% to £2.747 million, with gross Margin improving to 75% from 73.5%.
- Adjusted EBITDA turned positive at £76,000, a swing from a £227,000 loss a year earlier.
- The heart-valve Subsidiary RUA Structural Heart was spun out with £3 million of financing from the Leducq organisation.
- The UK medical devices and components Business grew revenue by around 32%, while Biomaterials licensing grew roughly 40%.
- Management is guiding to a return to net profitability in the second half of the current financial year.
The AIM-listed medical polymer group behind Elast-Eon reported its first period of positive adjusted EBITDA in interim results, alongside a spin-out of its heart-valve unit that reshapes the Balance Sheet ahead of a targeted return to net profit.
RUA Life Sciences (LSE:RUA), the AIM-quoted developer of the biostable Elast-Eon polymer used in long-term implantable medical devices, has told shareholders it turned adjusted EBITDA positive for the first time in the six months to 31 March 2026, alongside a headline gross margin of 75%. The interim results, published on 30 June 2026, mark a milestone for a business that has spent several years restructuring around contract Manufacturing after a heavier, R& Amp ;D-led past. The update follows a May announcement confirming the spin-out and £3 million financing of its Structural Heart subsidiary, concentrating the listed group on its cash-generative core.
What Happened
In its interim results for the half-year to 31 March 2026, RUA Life Sciences reported revenue of £2,747,000, up 6.1% from £2,589,000 a year earlier. Gross margin rose to 75% from 73.5% in H1 2025. Adjusted EBITDA came in at £76,000, a swing from a £227,000 loss a year earlier, while the post-tax loss narrowed to £183,000 from £641,000 and the operating loss improved to £234,000 from £685,000. Cash fell to £2,365,000, from £3,250,000 at 30 September 2025, a reduction the company attributed to receivables building as part of working-capital movements tied to growing trade.
Separately, on 12 May 2026 the company announced the spin-out of RUA Structural Heart Limited (RSH), its heart-valve subsidiary, alongside a £3 million financing round via convertible Unsecured Loan stock (CULS) issued to the Leducq organisation. RUA retains 100% of RSH's Equity for now, with £4.8 million of intercompany Debt capitalised into the new convertible instrument, and will no longer consolidate RSH's results, instead holding it as an Investment .
Why It Matters
For a company whose recent history includes a trading suspension and heavy losses, a positive adjusted EBITDA figure — even a modest £76,000 — is a symbolic threshold. It signals the contract manufacturing and biomaterials licensing operations now cover their own costs on an adjusted basis, a target pursued since pivoting strategy roughly two years ago. The RSH spin-out is equally significant: it removes a capital-intensive, pre-revenue heart-valve programme from the accounts, letting the market assess RUA primarily as a profitable, growing contract manufacturer (CDMO), while retaining upside through its equity stake.
Latest Financial and Operational Performance
Growth was uneven across segments. The UK medical devices and components business grew revenue by around 32%, and Biomaterials — which licenses Elast-Eon to third-party device makers — grew roughly 40-41% to about £490,000. Abiss, the French CDMO business acquired in September 2024, saw revenue decline by approximately 23% to around £1.0 million, attributed to customer inventory rationalisation rather than lost underlying Demand . Administrative costs fell by around 8%.
These figures build on a stronger full-year picture: in results for the 18-month period ended 30 September 2025 (following a change of accounting reference date), the company reported total revenue of £6.7 million, more than double the £2.2 million reported for the prior 12-month period to March 2024, and full-year EBITDA turned positive at roughly £0.4 million, against a £1.6 million loss previously. Chairman Geoff Berg said the group's two-year objectives of doubling revenue, cutting cash burn and reaching profitability had been achieved ahead of schedule, helped by the Abiss Acquisition .
Key Numbers
- Revenue, H1 to 31 March 2026: £2.747m, up 6.1% year-on-year
- Gross margin, H1 to 31 March 2026: 75% (H1 2025: 73.5%)
- Adjusted EBITDA, H1 to 31 March 2026: £76k profit (H1 2025: £227k loss)
- Post-tax loss, H1 to 31 March 2026: £183k (H1 2025: £641k)
- Cash at 31 March 2026: £2.365m (30 September 2025: £3.25m)
- 18 months to 30 September 2025: revenue £6.7m; EBITDA c.£0.4m positive
- RSH spin-out financing: £3m CULS from the Leducq organisation, plus £4.8m intercompany debt capitalised
Growth Opportunities
Management's stated ambition is to double group revenue again within roughly two years, building on Biomaterials licensing momentum and the expanding UK CDMO order book. The Elast-Eon platform underpins that pipeline: as a biostable, long-term implantable polyurethane, it is licensed into third-party devices, giving RUA a royalty-and-supply relationship with device makers beyond its own manufacturing capacity. The RSH spin-out is also a growth lever in its own right — it targets a heart-valve device for rheumatic heart disease patients in low- and middle-income countries using proprietary AurTex material, now funded with dedicated external Capital rather than group cash. Management guided that the group is projected to reach net profitability in the second half of the current financial year.
Risks Investors Should Know
RUA remains a small-cap company with a Market Capitalisation around £7 million and thin trading Liquidity , which can amplify share-price moves on newsflow. Cash consumption in Working Capital — an £885,000 reduction in H1 2026 — shows how growing receivables can pressure liquidity even as trading improves. Abiss's revenue decline highlights customer concentration and inventory-cycle risk within the CDMO business. The RSH spin-out leaves RUA holding an equity stake whose value depends on RSH raising further external financing and advancing a device not yet commercially approved; the retained stake is expected to dilute towards, but not below, 62% ahead of RSH's next funding round. Regulatory, clinical and funding risks remain material, as with any small-cap medical device business.
What to Watch Next
Investors should watch for confirmation of net profitability in the second half, progress on RSH's own funding round and clinical milestones, and whether Abiss's order book stabilises. Further RNS updates on working capital, CDMO contract wins, or Biomaterials licensing deals will help gauge whether the EBITDA swing is durable rather than a single-period inflection.
Outlook
RUA Life Sciences' (LSE:RUA) first half to March 2026 delivered on two fronts that matter most to a company emerging from a loss-making past: a maiden positive adjusted EBITDA figure and a 75% gross margin underscoring the value of its Elast-Eon-based, higher-margin product mix. The RSH spin-out sharpens the case further by separating a capital-hungry early-stage programme from the core, cash-generative CDMO business. The numbers are still small in absolute terms, and cash consumption bears watching, but management's guidance of a return to net profit in the second half gives investors a clear near-term marker against which to judge progress.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...